First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial by Lee, Siow Ming, Prof, Khan, Iftekhar, MSc, Upadhyay, Sunil, MD, Lewanski, Conrad, FRCP, Falk, Stephen, MD, Skailes, Geraldine, FRCR, Marshall, Ernie, MD, Woll, Penella J, Prof, Hatton, Matthew, FRCR, Lal, Rohit, MRCP, Jones, Richard, FRCR, Toy, Elizabeth, FRCR, Chao, David, DPhil, Middleton, Gary, MD, Bulley, Sue, SRN, Ngai, Yenting, BSc, Rudd, Robin, MD, Hackshaw, Allan, Prof, Boshoff, Chris, Prof

Get full text